Page last updated: 2024-12-05

trimethyl phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trimethyl phosphate: request from searcher; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trimethyl phosphate : A trialkyl phosphate that is the trimethyl ester of phosphoric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10541
CHEMBL ID1236486
CHEBI ID46324
SCHEMBL ID19941
MeSH IDM0044799

Synonyms (63)

Synonym
unii-z1e45tmw1z
trimethylfosfat
z1e45tmw1z ,
AKOS009029142
CHEMBL1236486
trimethylphosphate
nsc-58985
wln: 1opo&o1&o1
methyl phosphate, (meo)3po
nsc58985
trimethoxyphosphine oxide
nci-c03781
CHEBI:46324 ,
512-56-1
trimethyl orthophosphate
trimethyl phosphate
o,o,o-trimethyl phosphate
phosphoric acid, trimethyl ester
phosphoric acid trimethyl ester
inchi=1/c3h9o4p/c1-5-8(4,6-2)7-3/h1-3h
nsc 58985
trimethylfosfat [czech]
ai3-05905
hsdb 5090
ccris 610
einecs 208-144-8
phosphate, trimethyl-
tzz ,
trimethyl phosphate, >=99%
trimethyl phosphate, 97%
BMSE000774
P0271
A804739
NCGC00248617-02
NCGC00248617-01
tox21_302740
NCGC00256562-01
cas-512-56-1
dtxcid101403
dtxsid1021403 ,
tox21_201576
NCGC00259125-01
FT-0689821
tmp (phosphate)
trimethyl phosphate [hsdb]
SCHEMBL19941
po(ome)3
p(o)(ome)3
trimethylphosphoric acid
dimethylphosphonomethanol
p(o)(och3)3
trimethyl phosphoric acid
trim ethyl phosphate
(ch3o)3po
mfcd00008348
trimethyl phosphate, saj first grade, >=95.0%
trimethyl phosphate (tmp)
azidotriphenylmethane
Q2623529
AT32972
EN300-19167
HY-A0108A
CS-0646319

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Relatively slight hematologic changes (reduced hemoglobin, hematocrit, erythrocyte counts, increased reticulocyte numbers, and thrombocyte counts as well as a shift in the differential blood count) at 100/50 mg/kg are interpreted as changes most probably secondary to the other toxic effects."( Trimethylphosphate: a 30-month chronic toxicity/carcinogenicity study in Wistar rats with administration in drinking water.
Bomhard, EM; Krinke, GJ; Rossberg, WM; Skripsky, T, 1997
)
0.3
" Results suggest that several OPFRs (BPDP, EHDP; IPP, TMPP; TPHP and TDCIPP) produced adverse effects in multiple target organs at concentrations comparable to the two BFRs."( Toxicity profiling of flame retardants in zebrafish embryos using a battery of assays for developmental toxicity, neurotoxicity, cardiotoxicity and hepatotoxicity toward human relevance.
Alday, A; Alzualde, A; Behl, M; Hsieh, JH; Muriana, A; Paules, RS; Quevedo, C; Sipes, NS; Tice, RR,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" The dosage of 100 mg/kg was reduced to 50 mg/kg in week 54 for reasons of tolerance, and the animals were euthanized in week 100."( Trimethylphosphate: a 30-month chronic toxicity/carcinogenicity study in Wistar rats with administration in drinking water.
Bomhard, EM; Krinke, GJ; Rossberg, WM; Skripsky, T, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
insect attractantA chemical that attracts insects.
NMR chemical shift reference compoundAny compound that produces a peak used to reference an NMR spectrum during data pre-processing.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
trialkyl phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency90.08780.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency34.65610.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency10.95920.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency61.62820.000221.22318,912.5098AID1259243
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency24.33650.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency30.88730.001022.650876.6163AID1224838
retinoid X nuclear receptor alphaHomo sapiens (human)Potency12.40070.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.96500.001530.607315,848.9004AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency21.87510.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency61.62820.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency48.95300.000229.305416,493.5996AID1259244
activating transcription factor 6Homo sapiens (human)Potency2.20520.143427.612159.8106AID1159516
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency31.15300.154917.870243.6557AID1346891
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.61630.000323.4451159.6830AID743066
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency48.95300.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency48.95300.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1880635Tanol-water partition coefficient, logP of compound by shake flask method based 31P-NMR analysis2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Studying Lipophilicity Trends of Phosphorus Compounds by
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (22.50)18.7374
1990's5 (12.50)18.2507
2000's12 (30.00)29.6817
2010's11 (27.50)24.3611
2020's3 (7.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.30 (24.57)
Research Supply Index3.78 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index63.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other42 (97.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]